23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults
- 1 May 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (8) , 1210-1213
- https://doi.org/10.1097/00002030-200405210-00018
Abstract
23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.Keywords
This publication has 6 references indexed in Scilit:
- Cotrimoxazole prophylaxis in adults infected with HIV in low-income countriesCurrent Opinion in Infectious Diseases, 2001
- Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adultsAIDS, 2001
- Evaluation of Effectiveness of the 23-Valent Pneumococcal Capsular Polysaccharide Vaccine for HIV-Infected PatientsArchives of internal medicine (1960), 2000
- 23-valent pneumococcal vaccination and HIV.The Lancet, 2000
- 23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trialThe Lancet, 2000
- Increased Plasma Human Immunodeficiency Virus Type 1 Burden following Antigenic Challenge with Pneumococcal VaccineThe Journal of Infectious Diseases, 1996